Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF‐cleaving protease activity

@article{Mori2002PredictingRT,
  title={Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF‐cleaving protease activity},
  author={Yoshitaka Mori and Hideo Wada and Esteban C. Gabazza and Nobuyuki Minami and Tsutomu Nobori and Hiroshi Shiku and Hideo Yagi and Hiromichi Ishizashi and Masanori Matsumoto and Yoshihiro Fujimura},
  journal={Transfusion},
  year={2002},
  volume={42}
}
BACKGROUND: Severe deficiency of vWF‐cleaving protease (vWF‐CPase) activity was recently found in patients with thrombotic thrombocytopenic purpura (TTP). Although the survival of patients with TTP has been dramatically improved with plasma exchange (PE), there are still many patients who are refractory to PE and immunosuppressive therapy. 
Treatment with or without plasma exchange for patients with acquired thrombotic microangiopathy not associated with severe ADAMTS13 deficiency: a propensity score–matched study
Therapeutic plasma exchange (TPE) is a proven treatment for thrombotic thrombocytopenic purpura (TTP) characterized by severe ADAMTS13 deficiency, but the efficacy of TPE in suspected TTP with anExpand
Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura.
TLDR
It is shown that a severe deficiency of the von Willebrand factor (VWF)–cleaving protease ADAMTS13 is specific for thrombotic thromBocytopenic purpura (TTP) and is in agreement with the results of the studies. Expand
Implementation of a rapid assay of ADAMTS13 activity was associated with improved 30‐day survival rate in patients with acquired primary thrombotic thrombocytopenic purpura who received platelet transfusions
Platelet (PLT) transfusions are probably harmful in patients with acquired idiopathic thrombotic thrombocytopenic purpura (aTTP). Introduction of a rapid assay for ADAMTS13 activity should reduce theExpand
Severe deficiency of VWF‐cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients
TLDR
It was hypothesized that severe ADAMTS13 deficiency is associated with a distinct TMA subpopulation and this data indicates that severe deficiency of ADAMts13 activity is a biologic risk factor for thrombotic microangiopathy. Expand
Thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Large and unusually large von Willebrand factor (vWf) multimers may be responsible for systemic platelet aggregation in thrombotic thrombocytopenic purpura (TTP). This possibility is supported byExpand
Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
TLDR
Intensive immunosuppressive therapy with rituximab appears to be effective as salvage therapy, and ongoing clinical trials should determine whether adjuvant ritUXimab with plasma exchange also is beneficial at first diagnosis. Expand
Von Willebrand factor , ADAMTS 13 , and thrombotic thrombocytopenic purpura
Discoveries during the past decade have revolutionized our understanding of idiopathic thrombotic thrombocytopenic purpura (TTP). Most cases in adults are caused by acquired autoantibodies thatExpand
Advantages and limits of ADAMTS13 testing in the prognostic assessment of thrombotic thrombocytopenic purpura.
TLDR
A number of laboratory assays for measuring ADAMTS13 and related autoantibodies have been developed and current knowledge on the diagnostic and prognostic value of ADAMts13 and anti-ADAM TS13 assays is summarized. Expand
Intensive Plasma IgG Removal Therapy for Severe Thrombotic Thrombocytopenic Purpura
TLDR
A patient with acquired TTP is successfully treated by repeated courses of IgG removal from the plasma, the efficacy of which was assessed serially by the determination of plasma VWF-CP activity and the titration of plasma inhibitor. Expand
Thrombotic thrombocytopenic purpura: Results of the patients with thrombotic microangiopathies across Japan by ADAMTS13 analysis during 1998–2008
TLDR
Severe deficiency of plasma ADAMTS13 activity (ADAMts13:AC) is more specific for TTP but not for HUS, and two typical phenotypes of TMAs are hemolytic‐uremic syndrome (HUS) andThrombotic thrombocytopenic purpura (TTP). Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.
A platelet-agglutinating factor has been detected in the plasma of some patients during episodes of thrombotic thrombocytopenic purpura (TTP).1 , 2 Agglutination induced in vitro by this plasma fac...
Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.
TLDR
It is concluded that acquired as well as constitutional deficiency of the vWF-cleaving protease may predispose to TTP. Expand
Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.
TLDR
It is suggested that, in contrast to protease deficient patients without circulating inhibitor, complementary therapy including immunosuppressive treatment, vincristine and/or splenectomy is indicated in patients with acquired inhibitors of vWF-cleaving protease. Expand
Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura.
TLDR
The data suggest that the unusually large vWF multimers found in TTP patients may be caused by deficient vWF-cleaving protease activity, and may be used as a sensitive diagnostic tool for identification of subjects with a latent TTP tendency. Expand
von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura.
TLDR
The results indicate that the etiologies of classic and BMT-associated TTP are indeed different and provide an explanation for the lack of success of plasma exchange in B MT- associated TTP. Expand
Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura
TLDR
It is suggested that vWf‐platelet interactions are involved in the platelet clumping process that characterizes TTP, and in the one unresponsive single episode TTP patient, vWF on single platelets remained elevated, and platelet aggregates persisted, until her death. Expand
Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.
TLDR
Inhibitory antibodies against von Willebrand factor-cleaving protease occur in patients with acute thrombotic throm bocytopenic purpura, suggesting that a deficiency of this protease is likely to have a critical role in the pathogenesis of platelet thromBosis in this disease. Expand
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
TLDR
Nonfamilial thrombotic throm bocytopenic purpura is due to an inhibitor of von Willebrand factor-cleaving protease, whereas the familial form seems to be caused by a constitutional deficiency of the protease. Expand
Abnormalities of von willebrand factor multimers in drug‐associated thrombotic microangiopathies
TLDR
The finding of vWF multimeric abnormalities during serial analysis of plasma samples from five of six patients with drug‐associated thrombotic microangiopathy suggests the possibility that ULvWF forms derived from damaged or stimulated endothelial cells, along with the largest plasma vWF multimers, may be involved in the intravascular platelet clumping that is an essential part of the pathophysiology of this disorder. Expand
Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura.
TLDR
It is concluded that an activity in FFP, and its cryosupernatant fraction, promoted the rapid in vivo disappearance of unusually large vWF multimers from the plasma of two patients with chronic relapsing TTP in remission, and plasma exchange reversed the abnormality in a third patient who was in partial remission. Expand
...
1
2
3
4
5
...